Efficacy and Safety Study of Deferasirox in Patients With Non-transfusion Dependent Thalassemia

Summary

Assessed the efficacy of deferasirox in patients with non-transfusion dependent thalassemia based on change in liver iron concentration from baseline after 52 weeks of treatment. Provided further assessment of the long-term efficacy and safety of deferasirox in NTDT patients with iron overload (LIC ≥ 5 mg Fe/g liver dw and SF ≥ 300 ng/mL) for up to 260 weeks.

Timeline

Start

2012-12-06

Primary completion

2015-01-03

Completion

2019-01-17

Drugs

Indications